Drugs / CMAB007
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | China (NMPA) | — | asthma | — | “CMAB007 新药申请于 2021 年 10 月向国家药品监督管理局递交” jemincare.com ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07246252 | Mar → Sep 2024 | — | Taizhou Mabtech Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT06365879 | Jun 2024 → Jan 2026 | chronic idiopathic urticaria | Taizhou Mabtech Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03468790 | May 2018 → Jan 2021 | allergic asthma | Shanghai Biomabs Pharmaceutical Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMAB007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03468790 ↗ |
| Modality | Monoclonal antibody | “CMAB007(recombinant humanized anti-IgE monoclonal antibody for injection )” NCT03468790 ↗ |
| Route | Subcutaneous | “300mg, SC, Q4W” NCT06365879 ↗ |